Alzheimer''s and Dementia: Translational Research and Clinical Interventions最新文献

{"title":"The relationship between neurofilament light chain and depressive symptoms according to cognitive status","authors":"Federico Bellelli, Jeremy Raffin, Davide Angioni, Julie Romana, Maria Soto, Julien Delrieu, Philipe De Souto Barreto, for the MAPT/DSA study group","doi":"10.1002/trc2.70048","DOIUrl":"https://doi.org/10.1002/trc2.70048","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> INTRODUCTION</h3>\u0000 \u0000 <p>Although recent studies have suggested a positive association between plasma neurofilament light chain (NfL) and depressive symptoms, the moderating effect of cognitive performance on this relationship remains unclear. The aim of this study was to investigate the association between NfL and depressive symptoms in a population of community-dwelling older adults and to determine whether cognitive status could modify this relationship.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> METHODS</h3>\u0000 \u0000 <p>This is a secondary analysis of the Multidomain Alzheimer Preventive Trial (MAPT), including 512 individuals (60.2% women) with a median age of 76 years (interquartile range [IQR]: 7) and with available data for plasmatic NfL levels. Depressive symptoms and cognitive status were assessed using the 15-item Geriatric Depression Scale (GDS-15) and the Clinical Dementia Rating (CDR) scale, respectively. Multivariable linear regression analyses were conducted to explore the cross-sectional association between GDS-15 (dependent variable) and plasma NfL levels (pg/mL). The interaction between CDR status (binary: 0 or 0.5) and NfL levels in relation to depressive symptoms was also examined, followed by exploratory simple-slope analyses according to CDR status.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> RESULTS</h3>\u0000 \u0000 <p>No significant association was observed between GDS-15 scores and plasma NfL levels (<i>B</i> = 0.002, standard error [SE] = 0.001, <i>p</i> = 0.08) in the entire sample. Although the CDR–NfL interaction was not significant (<i>B</i> = 0.003, SE = 0.002, <i>p</i> = 0.17), exploratory simple-slope analyses revealed that elevated NfL levels were associated with GDS-15 scores (<i>N</i> = 233, <i>B</i> = 0.004, SE = 0.002, <i>p</i> = 0.03) among individuals with a CDR 0.5, but not among those with a CDR 0 (<i>N</i> = 186, <i>p</i> = 0.81).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> DISCUSSION</h3>\u0000 \u0000 <p>NfL levels were not significantly associated with GDS-15 in a population of community-dwelling older adults without dementia. Although no significant CDR–NfL interaction was detected, exploratory analyses suggest that plasma NfL might be associated with GDS-15 scores only among people with a CDR 0.5 (indicative of mild cognitive impairment). Further studies with larger sample sizes are needed to elucidate the potential biological differences in depressive symptoms across different cognitive statuses.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Highlights</h3>\u0000 \u0000 <div>\u0000 ","PeriodicalId":53225,"journal":{"name":"Alzheimer''s and Dementia: Translational Research and Clinical Interventions","volume":"11 2","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/trc2.70048","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143925872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety considerations of semaglutide in the potential treatment of Alzheimer's disease: A pooled analysis of semaglutide in adults aged ≥ 65 years","authors":"Marwan Sabbagh,&nbsp;Cristina Boschini,&nbsp;Sharon Cohen,&nbsp;Magnus Fugger,&nbsp;Frank Jessen,&nbsp;Sune Dandanell,&nbsp;Sue D. Pedersen,&nbsp;Luis Rafael Solís Tarazona,&nbsp;Vanita R. Aroda","doi":"10.1002/trc2.70076","DOIUrl":"https://doi.org/10.1002/trc2.70076","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> INTRODUCTION</h3>\u0000 \u0000 <p>The evoke/evoke+ trials are investigating semaglutide in a population with early Alzheimer's disease (AD). Specific analyses of semaglutide safety data in older adults are limited; therefore, in the current analysis, we aimed to evaluate safety considerations with semaglutide in adults ≥ 65 years.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> METHODS</h3>\u0000 \u0000 <p>Adverse event (AE) data from three semaglutide phase 3a programs in participants ≥ 65 years with type 2 diabetes and/or overweight/obesity were pooled. Change in body weight was also assessed in a smaller subset of participants ≥ 65 years.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> RESULTS</h3>\u0000 \u0000 <p>The analysis included 3529 participants ≥ 65 years. Baseline mean age and body mass index in participants ≥ 65 years were 69.3 to 70.2 years and 29.7 to 35.4 kg/m², respectively, compared to 47.8 to 58.5 years and 31.3 to 36.7 kg/m² in the overall population. AEs with semaglutide occurred in 73.6% to 92.4% of participants ≥ 65 years versus 73.2% to 90.8% of the overall population. AEs with semaglutide leading to permanent discontinuation appeared to be more frequent in participants ≥ 65 years (9.3%–12.4%) versus the overall population (5.7%–8.7%). Gastrointestinal disorders were the most frequently reported AEs with semaglutide in participants ≥ 65 years (44.6%–73.8%) and in the overall population (39.1%–73.4%). Participants aged ≥ 65 years receiving semaglutide had an estimated weight loss of 3.8% at week 52 compared to 0.1% with placebo.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> DISCUSSION</h3>\u0000 \u0000 <p>Age ≥ 65 years did not appear to affect the safety considerations of semaglutide. The ongoing evoke/evoke+ trials will elucidate the balance of efficacy and safety in the treatment of early AD with semaglutide.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Highlights</h3>\u0000 \u0000 <div>\u0000 <ul>\u0000 \u0000 <li>This was a post hoc analysis evaluating adverse event (AE) data of semaglutide in people ≥ 65 years.</li>\u0000 \u0000 <li>The most common AE with semaglutide was gastrointestinal (GI).</li>\u0000 \u0000 <li>GI event rates were similar in people ≥ 65 years and the overall study populations.</li>\u0000 </ul>\u0000 </div>\u0000 </section>\u0000 </div>","PeriodicalId":53225,"journal":{"name":"Alzheimer''s and Dementia: Translational Research and Clinical Interventions","volume":"11 2","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/trc2.70076","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143914374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Constructive engagement in cognitive stimulation therapy groups among people with dementia: A mixed-methods study","authors":"Anna Yan Zhang,&nbsp;Gloria Hoi Yan Wong,&nbsp;Terry Yat Sang Lum,&nbsp;Bob Woods,&nbsp;Aimee Spector","doi":"10.1002/trc2.70075","DOIUrl":"https://doi.org/10.1002/trc2.70075","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Introduction&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Clinical guidelines recommend personalized activities and group cognitive stimulation therapy (CST) for promoting cognition, independence, and well-being in persons with dementia. Constructive engagement (CE), the state of being occupied positively in purposeful activities, is theoretically an essential process in personalized activities and CST. However, whether CE develops over time and what contributes to it are unknown. We investigated changes in CE during CST and its contributors.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;This is a mixed-methods study. We used time sampling to record the time proportion of persons with dementia (&lt;i&gt;n&lt;/i&gt; = 113) spent in constructive, passive, non–task-related engagement and non-engagement during early, middle, and late phases in a 14-session group CST. We tested changes in time proportion between phases using repeated analysis of variance (ANOVA). We analyzed qualitative interviews of CST facilitators (&lt;i&gt;n&lt;/i&gt; = 12) thematically to explore contributors to CE.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Persons with dementia spent 51% and 46% of their time in constructive and passive engagement, respectively. Time of engagement in non–task-related activities and non-engagement was minimal. CE remained stable at around 50% of activity time throughout the intervention course, except for a slight increase from the early to middle phase (48% to 55%, F (2224) = 3.779, &lt;i&gt;p&lt;/i&gt; &lt; 0.05). Age (&lt;i&gt;r &lt;/i&gt;= −0.26, &lt;i&gt;p&lt;/i&gt; &lt; 0.01), cognitive function (&lt;i&gt;r &lt;/i&gt;= −0.29, &lt;i&gt;p&lt;/i&gt; &lt; 0.01), and activities of daily living (&lt;i&gt;r &lt;/i&gt;= 0.20, &lt;i&gt;p&lt;/i&gt; &lt; 0.05) at baseline were significantly correlated with CE, but gender and education were not. Contributors to CE include (1) tailoring activities, (2) using group dynamics, and (3) promoting positive experiences.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Discussions&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Group CST engages persons with dementia well, regardless of their differences in gender and literacy levels. CE remained relatively stable during CST, and younger, more physically and cognitively able people showed slightly greater CE. In group-based interventions, facilitators' skills and techniques could enhance CE. Future studies may focus on how CE as a plausible change mechanism further improves the intervention outcomes of persons with dementia.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Highlights&lt;/h3&gt;\u0000 \u0000 &lt;div&gt;\u0000 &lt;ul&gt;\u0000 \u0000 ","PeriodicalId":53225,"journal":{"name":"Alzheimer''s and Dementia: Translational Research and Clinical Interventions","volume":"11 2","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/trc2.70075","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143865827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AI approaches for phenotyping Alzheimer's disease and related dementias using electronic health records","authors":"Sara Knox,&nbsp;Stephanie Aghamoosa,&nbsp;Paul M. Heider,&nbsp;Maxwell Cutty,&nbsp;Andrew Wright,&nbsp;Dmitry Scherbakov,&nbsp;Gabriel Hood,&nbsp;Sara A. Nolin,&nbsp;Jihad S. Obeid","doi":"10.1002/trc2.70089","DOIUrl":"https://doi.org/10.1002/trc2.70089","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; INTRODUCTION&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The current standard electronic (e-)phenotype for identifying patients with Alzheimer's disease and related dementias (ADRD) from medical claims data yields suboptimal diagnostic accuracy. This study leveraged artificial intelligence (AI)–based text-classification methods to improve the identification of patients with dementia due to ADRD using clinical notes from electronic health records (EHRs).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; METHODS&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;EHR data for patients aged ≥ 64 (&lt;i&gt;N&lt;/i&gt; = 4000) from an academic medical center were used. The cohort included 1000 patients with ADRD per the Chronic Conditions Warehouse (CCW) algorithm for ADRD (i.e., at least one ADRD International Classification of Diseases, Tenth Revision codes [ICD-10 code]) and 3000 matched controls without ADRD (i.e., no CCW codes). We trained several AI-based text-classification models, including bag-of-words models, deep learning, and large language models (LLMs), to make ADRD determinations from clinical notes. The performance of each model was evaluated against “gold standard” manual chart review.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; RESULTS&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;A foundational LLM derived from Llama 2 demonstrated superior performance in identifying patients with ADRD (area under the curve [AUC] = 0.9534, &lt;i&gt;F&lt;/i&gt;&lt;sub&gt;1&lt;/sub&gt; score 0.8571) compared to both the current standard CCW algorithm (AUC = 0.8482, &lt;i&gt;F&lt;/i&gt;&lt;sub&gt;1&lt;/sub&gt; score 0.8323, although only the AUC was statistically significantly different) and other AI-based models. Several of the AI-based models, including convolutional neural networks, also outperformed the CCW algorithm.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; DISCUSSION&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;These findings highlight the potential of AI-based text-classification methods to optimize the automated identification of patients with ADRD using rich EHR data. However, the success of this approach depends on the quality of clinical notes, and more work is needed to refine and validate these methods across more diverse data sets.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Highlights&lt;/h3&gt;\u0000 \u0000 &lt;div&gt;\u0000 &lt;ul&gt;\u0000 \u0000 &lt;li&gt;The current e-phenotype for patients with Alzheimer's disease and related dementias (ADRD) in electronic health records has suboptimal diagnostic accuracy.&lt;/li&gt;\u0000 \u0000 &lt;li&gt;The study used artificial intelligence (AI)–based text classification methods to improve the detection of patients with A","PeriodicalId":53225,"journal":{"name":"Alzheimer''s and Dementia: Translational Research and Clinical Interventions","volume":"11 2","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/trc2.70089","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143871605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Supporting dementia caregivers: The role of “lived experience” and public health collaboration","authors":"Chelsea Kline,&nbsp;Elma Johnson,&nbsp;Ellen Tambor,&nbsp;Catherine Woodall Colcombe,&nbsp;Sam Fazio,&nbsp;Greg Woods,&nbsp;Dale Rivard,&nbsp;Gary Epstein-Lubow","doi":"10.1002/trc2.70087","DOIUrl":"https://doi.org/10.1002/trc2.70087","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <p>Developing effective resources to support dementia caregivers requires collaboration between public health officials and those with lived experience of caregiving. This perspective highlights why this collaboration is so crucial to elevating public health practice and describes the unique efforts of the BOLD Public Health Center of Excellence on Dementia Caregiving to foster this collaboration through its Lived Experience Advisory Groups (LEAG). The LEAGs convene people living with dementia, family caregivers, and public health officials to guide the development of resources that state, local, and tribal public health departments can use to support dementia caregivers in their communities. Through these interactions, public health strategies become more responsive to the real-life needs of caregivers and people living with dementia. This approach not only enhances caregiver support but also strengthens and aligns public health initiatives with the lived experiences of the populations they serve, fostering health equity and community engagement. This paper highlights key activities, outcomes, and future directions for integrating lived experience and public health perspectives into practice, offering a new and innovative model for other organizations seeking to improve support for dementia caregivers.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Highlights</h3>\u0000 \u0000 <div>\u0000 <ul>\u0000 \u0000 <li>Public engagement enhances responsiveness and effectiveness of public health programs.</li>\u0000 \u0000 <li>LEAGs allow people with lived experience to help shape programs and facilitate collaboration with public health professionals.</li>\u0000 \u0000 <li>Local and state health agencies can improve engagement by implementing LEAGs.</li>\u0000 \u0000 <li>Increasing diversity of people with lived experience can improve outcomes for communities disproportionately impacted by dementia.</li>\u0000 </ul>\u0000 </div>\u0000 </section>\u0000 </div>","PeriodicalId":53225,"journal":{"name":"Alzheimer''s and Dementia: Translational Research and Clinical Interventions","volume":"11 2","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/trc2.70087","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143871606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Machine learning–enhanced screening funnel for clinical trials in Alzheimer's disease","authors":"Scott Gladstein,&nbsp;Liuqing Yang,&nbsp;Dustin Wooten,&nbsp;Xin Huang,&nbsp;Robert Comley,&nbsp;Qi Guo,&nbsp;the Alzheimer's Disease Neuroimaging Initiative","doi":"10.1002/trc2.70084","DOIUrl":"https://doi.org/10.1002/trc2.70084","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> INTRODUCTION</h3>\u0000 \u0000 <p>Alzheimer's disease (AD) clinical trials with therapeutic interventions require hundreds of subjects to be studied over many months/years due to variable and slow disease progression. This article presents a novel screening paradigm integrating disease progression models to improve trial efficiency by identifying appropriate candidates for early phase clinical studies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> METHODS</h3>\u0000 \u0000 <p>A traditional screening funnel is enhanced using machine learning models, including 3D convolutional neural networks and ensemble models, which integrate neuroimaging, demographic, genetic, and clinical data.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> RESULTS</h3>\u0000 \u0000 <p>This approach predicts clinical progression (2-year Clinical Dementia Rating Sum of Boxes change &gt; 1) with an area under the curve of 0.836. Incorporating it into trials (with maximized sensitivity/specificity optimization) could reduce the number of subjects required by 55%, shorten recruitment by 13 months, and reduce screening amyloid positron emission tomography scans by 72%.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> DISCUSSION</h3>\u0000 \u0000 <p>By reducing patient burden and shortening timelines in clinical trials, this enhanced screening funnel could accelerate the development of AD therapies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Highlights</h3>\u0000 \u0000 <div>\u0000 <ul>\u0000 \u0000 <li>An innovative screening funnel was developed to improve Alzheimer's disease clinical trial efficiency.</li>\u0000 \u0000 <li>The funnel incorporates machine learning (ML)–based disease progression models.</li>\u0000 \u0000 <li>The ML model identifies patients with progression rate optimal for clinical trials.</li>\u0000 \u0000 <li>Unsuitable patients would fail early in the funnel before burdensome imaging procedures.</li>\u0000 \u0000 <li>This screening funnel is customizable to specific study needs.</li>\u0000 </ul>\u0000 </div>\u0000 </section>\u0000 </div>","PeriodicalId":53225,"journal":{"name":"Alzheimer''s and Dementia: Translational Research and Clinical Interventions","volume":"11 2","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/trc2.70084","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143865894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical factors predicting the rate of cognitive decline in a US memory clinic: An electronic health record study","authors":"Roy Adams,&nbsp;Jeannie-Marie Leoutsakos,&nbsp;Milap A. Nowrangi,&nbsp;Esther S. Oh,&nbsp;Paul B. Rosenberg,&nbsp;Konstantina Skolariki,&nbsp;Sevil Yasar,&nbsp;Peter P. Zandi,&nbsp;Constantine G. Lyketsos","doi":"10.1002/trc2.70070","DOIUrl":"https://doi.org/10.1002/trc2.70070","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; INTRODUCTION&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Dementia progression is heterogeneous and predicting who will decline quickly remains an open problem. Most work in this area has focused on volunteer-based cohorts, which are subject to recruitment biases. Instead, we examine predictors of rate of cognitive decline in cognitive assessment scores using electronic health record (EHR) data from a US memory clinic.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; METHODS&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Data include patients with their first memory clinic visit (baseline) between January 1, 2014 and May 31, 2024. We used a discrete-time model to identify significant predictors of baseline and 6 month change in Mini-Mental State Examination (MMSE) scores (Montreal Cognitive Assessment scores were converted to MMSE equivalents for analysis). Inverse probability weighting was used to account for selection and censoring biases and &lt;i&gt;p&lt;/i&gt; values were adjusted for multiple comparisons.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; RESULTS&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The cohort included 9583 patients, of which 7113 had a baseline cognitive assessment. Average MMSE at baseline was 23.2. Variables associated with lower baseline MMSE included female sex, non-White race, Medicaid enrollment, baseline dementia diagnosis, and cholinesterase inhibitor prescription, while higher scores were associated with prior diagnoses of chronic pain or fatigue. Quicker post-baseline decline was associated with older age, dementia diagnoses, and cholinesterase inhibitor prescription, while slower decline was associated with a higher number of total prescriptions, distance from home to clinic, and Social Deprivation Index. Notably, rate of decline was not associated with mild cognitive impairment, other non-dementia cognitive impairment, or any of the comorbidities considered.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; DISCUSSION&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;While several significant predictors were identified, the lack of associations with broad categories of comorbidities and social determinants of health suggest that finer grained predictors may be needed. Additionally, the finding that cholinesterase inhibitor prescriptions predicted quicker decline merits additional investigation in real-world samples. The model developed in this work may serve as a first step toward an EHR-based progression risk tool.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Highlights&lt;/h3&gt;\u0000 \u0000 &lt;div&gt;\u0000 &lt;ul&gt;\u0000 \u0000 &lt;li&gt;In a memory clinic setting, faster decline in Mini-Mental State Examinat","PeriodicalId":53225,"journal":{"name":"Alzheimer''s and Dementia: Translational Research and Clinical Interventions","volume":"11 2","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/trc2.70070","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143865911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinically meaningful benefit and real-world evidence in Alzheimer's disease research and care","authors":"Robert Perneczky,&nbsp;Lutz Froelich","doi":"10.1002/trc2.70090","DOIUrl":"https://doi.org/10.1002/trc2.70090","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <p>In the realm of medical research, assessing novel therapies extends beyond statistical significance. The concept of meaningful benefits plays a pivotal role in determining the practical impact of interventions on patient outcomes. Clinical trials, which form the bedrock of evidence-based medicine, guide treatment decisions and shape health-care practices. While statistical significance remains a fundamental criterion, it falls short in fully evaluating the clinical relevance of therapeutic interventions. Clinically meaningful benefits focus on tangible improvements in patient health and well-being, transcending mere statistical thresholds. Key considerations include survival rates, symptom relief, functional status, and other patient-oriented outcomes. Determining meaningful benefits varies across diseases, patient populations, and available treatments. Balancing statistical rigor with clinical relevance is crucial. Overpowered trials may detect smaller differences than anticipated, necessitating careful interpretation. Researchers must view trial results through a patient-centric lens. Beyond survival, evaluating quality of life and side effects is equally relevant. Quantifying meaningful benefits involves metrics like numbers needed to treat and progression-free survival. Consistency across outcomes matters, as clinicians weigh gains in survival against improvements in quality of life. The pursuit of meaningful benefits elevates clinical trials from mere statistical exercises to patient-centered endeavors. Researchers, clinicians, and regulators must prioritize outcomes that genuinely matter to patients, ensuring that medical progress translates into meaningful improvements for them and their families.</p>\u0000 </section>\u0000 </div>","PeriodicalId":53225,"journal":{"name":"Alzheimer''s and Dementia: Translational Research and Clinical Interventions","volume":"11 2","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/trc2.70090","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143871607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Care staff perspectives of clinically meaningful outcomes for dementia residents","authors":"Alaine E. Reschke-Hernández,&nbsp;Martina Vasil,&nbsp;Emma King,&nbsp;Carson Woolums","doi":"10.1002/trc2.70091","DOIUrl":"https://doi.org/10.1002/trc2.70091","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; INTRODUCTION&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Non-pharmacological complementary and supportive care programs (CSCP, e.g., music therapy) are provided in addition to standard medical care for persons with dementia (PWD). Care staff observations are critical in assessing the clinical impact of CSCP on PWD. However, little is known about care staff experiences of CSCP and what factors influence documentation of outcomes. We sought to understand how care staff in Kentucky describe the clinically meaningful impact of CSCP on residents and themselves and learn what conditions enable and prohibit documentation.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; METHODS&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Four care staff from four dementia care facilities in Kentucky (representing non-profit, for-profit; rural, suburban, and urban areas) participated in this qualitative multiple case study. Participants were selected to reflect diverse care roles, identities, and experience. We collected data from eight semi-structured interviews (two per participant), 24 journal entries, four observations, photographs, and publicly available facility data. The use of multiple data types helped triangulate findings and enrich the analysis. Data were coded and analyzed for emerging themes.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; RESULTS&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Participants described CSCP as enhancing residents’ holistic well-being and being person-centered. CSCP also improved participants’ well-being and enhanced their sense of purpose. Primary documentation barriers were lack of time, prioritizing resident care over documentation, and top-down regulations. Technology both enabled and prohibited documentation, with routine being a key facilitator.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; DISCUSSION&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Our findings indicate that CSCP improve PWD's quality of life by fostering engagement, joy, and personalized care, consistent with person-centered care principles. Staff also benefit from reduced stress and improved morale. However, barriers exist, including time constraints and documentation challenges. Results may inform directions for future research, translation of CSCP from research to practice, and feasible measurement of clinically meaningful outcomes. The study underscores the importance of addressing systemic issues and advocating for policies that support sustainable, quality dementia care while enhancing both resident and staff well-being.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Highlights&lt;/h3&gt;\u0000 \u0000 &lt;div&gt;\u0000 &lt;ul&gt;\u0000 \u0000 ","PeriodicalId":53225,"journal":{"name":"Alzheimer''s and Dementia: Translational Research and Clinical Interventions","volume":"11 2","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/trc2.70091","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143871608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of long-term treatment with memantine on mortality in patients with major cognitive disorders: A systematic review and meta-analysis","authors":"Victoria Zolnowski-Kolp,&nbsp;Bruno Oquendo,&nbsp;Charlotte Havreng-Théry,&nbsp;Carmelo Lafuente-Lafuente,&nbsp;Joël Belmin","doi":"10.1002/trc2.70071","DOIUrl":"https://doi.org/10.1002/trc2.70071","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> BACKGROUND</h3>\u0000 \u0000 <p>Dementia is responsible for a reduction in life expectancy, and the effect of memantine on mortality is still poorly understood. Our aim was to evaluate the effect of long-term treatment with memantine on all-cause mortality.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> METHODS</h3>\u0000 \u0000 <p>In this systematic review and meta-analysis, we searched five databases from their creation to June 2024.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> RESULTS</h3>\u0000 \u0000 <p>We found 12 randomized trials (<i>n</i> = 4266) and 7 observational studies (<i>n</i> = 20,216). Treatment with memantine was associated with a reduction in all-cause mortality (risk ratios [RRs] 0.81, 95% CI: 0.72–0.92, <i>p</i> = 0.001). In the sensitivity analysis, the pooled RR was similar for randomized controlled trials (RCT) (RR 0.86) and non-randomized studies (RR 0.81) but pooled results from RCTs did not reach statistical significance (95% confidence interval [CI]: 0.59–1.26, <i>p</i> = 0.45), while they did for observational studies (95% CI: 0.70–0.95, <i>p</i> = 0.008), so we consider the overall evidence as of low certainty.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> CONCLUSION</h3>\u0000 \u0000 <p>Our results suggest that the use of memantine in patients with dementia may be associated with a reduction in all-cause mortality.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Highlights</h3>\u0000 \u0000 <div>\u0000 <ul>\u0000 \u0000 <li>Dementia reduces patients’ survival and the effect of long-term use of memantine on all-cause mortality is not well known.</li>\u0000 \u0000 <li>This systematic review and metanalysis included 19 studies including more than 24000 patients.</li>\u0000 \u0000 <li>We found that memantine in patients with dementia may be associated with a reduction in all-cause mortality.</li>\u0000 </ul>\u0000 </div>\u0000 </section>\u0000 </div>","PeriodicalId":53225,"journal":{"name":"Alzheimer''s and Dementia: Translational Research and Clinical Interventions","volume":"11 2","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/trc2.70071","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143850996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}